• Olmutinib* (BI 1482694 / HM61713) is first TKI therapy approved in South Korea for patients with EGFR T790M mutation-positive lung cancer
• Boehringer Ingelheim continues to accelerate development of the compound to bring innovative treatments to patients around the world as quickly as possible

INGELHEIM, Germany -- (BUSINESS WIRE) --

Olmutinib* (BI 1482694 / HM61713) has been approved in South Korea for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer, who had been previously treated with an EGFR tyrosine kinase inhibitor (TKI). The approval represents a first for regulatory authorities in South Korea and is a major breakthrough for patients. The compound will be distributed in South Korea by Hanmi Pharmaceutical Co. Ltd under the name olmutinib.

This approval is based on the results of the Phase I/II HM-EMSI-101 [NCT01588145] clinical trial which showed promising clinical activity for olmutinib (BI 1482694 / HM61713):

• Among 69 patients evaluable for response, objective response was observed by independent assessment in 62% of patients, including 32 (46%) whose tumour response had been confirmed at the time of data cut-off, 30 June 2015

• Disease control rate was 91% by independent assessment
• Majority of treatment-related adverse events (AEs) were mild-to-moderate and the most common included diarrhoea, nausea, rash and skin itching

Professor Keunchil Park, Director of Innovative Cancer Medicine Institute (ICMI) at Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea commented, “The approval of olmutinib is a great step forward for lung cancer patients in South Korea. This is an exciting and much needed new treatment option for the majority of EGFR mutation-positive lung cancer patients whose disease has become resistant to first-line TKI therapy, which can be a devastating development.”

Olmutinib (BI 1482694 / HM61713) is a novel third-generation, oral, EGFR mutation-specific TKI. It is currently in accelerated development through the ambitious ELUXA clinical trial programme with the aim to submit data and evidence to the US FDA and EU EMA in 2016. The pivotal Phase II trial ELUXA 1 (HM-EMSI-202 [NCT02485652]) is ongoing, enrolling EGFR T790M mutation-positive lung cancer patients who have become resistant to previous TKI treatment.

Dr Jörg Barth, Corporate Senior Vice President, Therapy Area Head Oncology, Boehringer Ingelheim said, “This first approval of olmutinib is an exciting milestone for the compound and we are working diligently to make this novel treatment option globally available to patients and physicians as quickly as possible.”

Boehringer Ingelheim and Hanmi Pharmaceutical Co. Ltd signed an exclusive license agreement in 2015 providing the German pharmaceutical company with worldwide exclusive rights, except in South Korea, China and Hong Kong. ZAI Lab has secured exclusive rights in China (including Hong Kong and Macau).

For references and notes to editor, please visit:

http://www.boehringer-ingelheim.com/press-release/south-korea-first-approve-next-generation-lung-cancer

Further Media Channels

www.facebook.com/boehringeringelheim

www.twitter.com/Boehringer

www.youtube.com/user/boehringeringelheim

Intended audiences

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

*Olmutinib (BI 1482694) is approved in South Korea for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer, who had been previously treated with an EGFR tyrosine kinase inhibitor (TKI). Olmutinib (BI 1482694) is not approved in other oncology indications.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160517005845/en/

CONTACT:

Boehringer Ingelheim
Corporate Communications
Media + PR
Reinhard Malin
Phone: +49 (6132) 77-90815
Fax: +49 6132 – 77 6601
Email: press@boehringer-ingelheim.com